ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

 

ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy
Avatar

Treatment-free Remission in Patients with Chronic Phase Chronic Myeloid Leukemia and Stable Deep Molecular Response Discontinuing Dasatinib (DASFREE)

By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Susanne Saussele
By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Susanne Saussele
0 views
January 2, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
Scientific Session 7: Treatment-free Remission
12:56
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Molecular Milestones Using the BCR-ABL1 qPCR Level and Doubling Time…

Feat. D. Kim
18:28
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

What Prevents the Disease from Relapsing after TKI Discontinuation

Feat. S. Mustjoki
11:10
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Treatment-free Remission in Patients with Chronic Phase Chronic Myel…

Feat. S. Saussele